The levels of dynorphin, α-neoendorphin and β-endorphin immunoreactivity (ir-DYN, ir-α-NEO, ir-β-E) were measured in the brain, pituitary and gut of rats subjected to a variety of manipulations. Water deprivation caused an increase in the ir-DYN and ir-α-NEO content in the hypothalamus and a decrease in the neurointermediate (NI) lobe of the pituitary. The ir-β-E level decreased in the hypothalamus and anterior lobe of the pituitary, while it increased in the Nl-pituitary. Food deprivation, as well as chronic fenfluramine (10–20 mg/kg) treatment increased, while acute muscimol (0.5 µg/10 µl) treatment decreased the ir-β-E, but not ir-DYN or ir-α-NEO content in the hypothalamus. The anterior pituitary content of ir-β-E was increased after food deprivation and decreased after chronic fenfluramine treatment. However, the ir-DYN and ir-α-NEO contents in the duodenum were markedly increased after food deprivation, while chronic fenfluramine treatment led to a dramatic decrease in the ir-DYN content. These results suggest that the levels of opioid peptides in the brain, pituitary and gut may be differentially and independently affected by alteration of the ingestive behavior.

Keywords:
Dynorphin, α-Neoendorphin, β-Endorphin, Food intake, Drinking, Dehydration
This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.